Close menu




August 4th, 2022 | 11:51 CEST

Nel, Altech Advanced Materials, Mercedes - It is getting exciting!

  • Hydrogen
  • Electromobility
  • Technology
Photo credits: pixabay.com

The challenges for the implementation of the energy turnaround are great. The desire to make greater use of renewable energy sources increased in light of the Ukraine war and the dependence on Russia that has become visible. Even after the highs of the Corona pandemic, supply chain issues and increased commodity prices continue to weigh. China's sabre-rattling illustrates that globalization not only brings benefits but also creates dependencies. In this respect, it is prudent for countries and industries to increasingly rely on national "solutions" or those that emanate from secure jurisdictions. In the megatrends of hydrogen technology and electromobility, investors should also keep an eye out for exciting companies from the second tier.

time to read: 3 minutes | Author: Carsten Mainitz
ISIN: NEL ASA NK-_20 | NO0010081235 , ALTECH ADV.MAT. NA O.N. | DE000A2LQUJ6 , MERCEDES-BENZ GROUP AG | DE0007100000

Table of contents:


    Altech Advanced Materials - When will the breakthrough come?

    "Innovation made in Germany" with the potential to turn industries upside down. In a nutshell, this is how one could characterize the Heidelberg-based Company, which is developing novel processes to make batteries significantly more powerful. The key lies in the coating technology for the anode material. Nanocoating with high-purity aluminium oxide and an enrichment of silicon can prevent the deposition of lithium particles on the electrodes. The problem of standard methods, which lead to a loss of capacity after the first charge, is thus eliminated. The "Silumina Anodes" could, in perspective, become the new industry standard.

    A recently published pre-feasibility study for the planned plant for ceramic coating of anode composite material in Schwarze Pumpe, south of Cottbus, underlined the great economic potential. The project's pre-tax net present value (NPV) is a substantial EUR 420 million. Heidelberg holds a 25% stake, bringing the value of the ownership interest to EUR 105 million. That is in contrast to the microcap's stock market value of well under EUR 10 million.

    At full capacity, 10,000 tons per year (tpa) can be produced. The Company expects an annual operating profit (EBITDA) of around EUR 52 million. The high profitability is reflected, among other things, in an internal rate of return (IRR) of 40% and a payback period for investments of only 3.1 years. On August 23, the Company invites its shareholders to the Annual General Meeting.

    Nel - Ambitious company valuation

    Nel hits the nerve of the times, offering solutions for the production, storage and distribution of hydrogen from renewable energy sources. Industry, energy and gas companies are among the growing customer base. The Norwegians have positioned themselves broadly and cover the entire value chain from hydrogen production to the manufacture of hydrogen refueling stations.

    Nel shareholders have had to show strong nerves in recent months. The shares are currently quoted at NOK 16, which means that the Company is valued at the equivalent of EUR 2.5 billion. Although analysts forecast a significant increase in sales from EUR 110 million in the current fiscal year to EUR 174 million in 2023, the Company is still in the red. The Company's valuation at around 25 times current sales still contains some advance praise. The analyst community also sees it that way; on average, the experts currently consider the shares to be exhausted. Nevertheless - Nel's recent announcement of a major order hints at how quickly it could see stronger-than-market-expected growth.

    "We are very pleased to announce the largest order to date for Nel. This project will demonstrate Nel's delivery and execution capabilities on a large scale and will be a valuable reference for future large orders. It will have a significant positive impact on Nel's finances, electrolyzer product and production costs, technology development and scale-up plans," said Håkon Volldal, CEO of Nel.

    The firm order for electrolyzer stacks is worth more than EUR 45 million. Production and delivery of the stacks is planned from February 2023 to mid-2024 at Nel's large-scale electrolyzer plant on Herøya.

    Mercedes-Benz Group - Better than the competition

    While Mercedes is optimistic about the future, competitor BMW recently rowed back. The Bavarians now expect a slight decline in sales in the current year. However, the operating margin should remain unchanged. Analysts did not like this, and BMW shares fell.

    According to consultancy PwC, production bottlenecks, supply chain problems and lockdowns in China have recently significantly slowed global sales of battery electric vehicles (BEVs). New registrations of e-cars in 14 selected markets doubled year-on-year in the first quarter, according to PwC, while the growth rate in the second quarter was "only" 62%. "In Europe, just under 1.5 million BEVs will be produced this year - at maximum capacity and without bottlenecks, it could be more than twice as many," said PwC industry expert Felix Kuhnert.

    Even if growth rates currently appear to be leveling off at a high level, Mercedes' strategic path of focusing on e-mobility is the right one. In addition, the brand is forcefully positioned in the luxury segment. That creates a clear profile. The spin-off of the truck division has additionally sharpened the equity story. The analysts at RBC recommend buying the shares of the South German company with a target price of EUR 90, which corresponds to an upside potential of a good 50%.


    All three companies mentioned have points of contact with the energy transition. Mercedes is focusing on electric mobility in the luxury segment. Nel benefits from the growth of the hydrogen sector. Altech from the second tier is interesting given the technology potential and the high valuation discount.


    Conflict of interest

    Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") may hold shares or other financial instruments of the aforementioned companies in the future or may bet on rising or falling prices and thus a conflict of interest may arise in the future. The Relevant Persons reserve the right to buy or sell shares or other financial instruments of the Company at any time (hereinafter each a "Transaction"). Transactions may, under certain circumstances, influence the respective price of the shares or other financial instruments of the Company.

    In addition, Apaton Finance GmbH is active in the context of the preparation and publication of the reporting in paid contractual relationships.

    For this reason, there is a concrete conflict of interest.

    The above information on existing conflicts of interest applies to all types and forms of publication used by Apaton Finance GmbH for publications on companies.

    Risk notice

    Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and the like on news.financial. These contents are exclusively for the information of the readers and do not represent any call to action or recommendations, neither explicitly nor implicitly they are to be understood as an assurance of possible price developments. The contents do not replace individual expert investment advice and do not constitute an offer to sell the discussed share(s) or other financial instruments, nor an invitation to buy or sell such.

    The content is expressly not a financial analysis, but a journalistic or advertising text. Readers or users who make investment decisions or carry out transactions on the basis of the information provided here do so entirely at their own risk. No contractual relationship is established between Apaton Finance GmbH and its readers or the users of its offers, as our information only refers to the company and not to the investment decision of the reader or user.

    The acquisition of financial instruments involves high risks, which can lead to the total loss of the invested capital. The information published by Apaton Finance GmbH and its authors is based on careful research. Nevertheless, no liability is assumed for financial losses or a content-related guarantee for the topicality, correctness, appropriateness and completeness of the content provided here. Please also note our Terms of use.


    Der Autor

    Carsten Mainitz

    The native Rhineland-Palatinate has been a passionate market participant for more than 25 years. After studying business administration in Mannheim, he worked as a journalist, in equity sales and many years in equity research.

    About the author



    Related comments:

    Commented by André Will-Laudien on September 30th, 2022 | 12:36 CEST

    Higher, faster, further: BYD, Infinity Stone, Porsche, Varta - The energy transition stock portfolio is wanted!

    • Mining
    • Gold
    • Electromobility
    • GreenTech

    The words "energy turnaround" are used a lot in public. The majority understand it to mean the use of GreenTech to generate energy while avoiding dangerous climate gases. Unfortunately, the leaks from the Nord Stream 2 pipeline, which is not in operation, are leaking the amount of gas into the atmosphere every day that the state of Denmark consumes in an entire week. This makes us painfully aware of how strongly warlike actions counteract efforts to save the climate. On the stock market, it is important to turn our gaze away from current events and toward a more peaceful future, where good ideas for sustainable change will also be rewarded. Which stocks belong in the portfolio?

    Read

    Commented by Juliane Zielonka on September 30th, 2022 | 10:59 CEST

    Biogen, XPhyto, BioNTech: Alzheimer's disease, depression, cancer - Pharma for life

    • Biotechnology
    • Pharma
    • Investments
    • Technology

    About 350 million people worldwide are affected by depression, a disorder of the brain. Each person also has a 16 to 20% chance of becoming depressed. Reason enough for the Canadian Company XPhyto Therapeutics to research a drug that is not addictive and can defeat the mental health-related medical condition. This week, Biogen, among others, achieved a breakthrough with an active substance against Alzheimer's disease. And if you follow the Bundesliga closely, you may be aware of the cases of testicular cancer among the players. Now BioNTech senses a new opportunity...

    Read

    Commented by Fabian Lorenz on September 29th, 2022 | 13:17 CEST

    Up to 200% share price potential: Kion, BioNTech, Aspermont in analyst check

    • Technology
    • Biotechnology
    • Investments

    The profit warning was a shock for Kion shareholders. Accordingly, the share price halved to EUR 20 in September alone. Now analysts are also slashing their estimates. The price targets for the forklift manufacturer are falling accordingly. Berenberg surprises with a high price target for the BioNTech share. At the same time, the analysts emphasize their hope for a continued generous dividend. Shareholders could thus be kept in good spirits until the next blockbuster. The roadshow of Aspermont in Germany has probably also created a good mood. At least the share price has jumped. The current consolidation could be an entry opportunity. Analysts see a price potential of over 200%.

    Read